The multicenter, single-arm, open-label Phase I/II trial (CodeBreak 100) demonstrated promising effects of sotorasib on locally advanced or metastatic KRAS G12C-mutated NSCLC patients previously received standard treatments. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.